Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models.

ABSTRACT: Despite decades of research, there is no specific therapy for acute pancreatitis (AP). In the current study, we have evaluated the efficacy of pirfenidone, an antiinflammatory and antifibrotic agent that is approved by the FDA for treatment of idiopathic pulmonary fibrosis (IPF), in ameliorating local and systemic injury in AP. Our results suggest that treatment with pirfenidone in therapeutic settings (e.g., after initiation of injury), even when administered at the peak of injury, reduces severity of local and systemic injury and inflammation in multiple models of AP. In vitro evaluation suggests that pirfenidone decreases cytokine release from acini and macrophages and disrupts acinar-macrophage crosstalk. Therapeutic pirfenidone treatment increases IL-10 secretion from macrophages prec

SUBMITTER: Palathingal Bava E 

PROVIDER: S-EPMC8855813 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature